461 related articles for article (PubMed ID: 31016733)
1. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
2. Neurokinin 1 Receptor Antagonists for Pruritus.
Alam M; Buddenkotte J; Ahmad F; Steinhoff M
Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
[TBL] [Abstract][Full Text] [Related]
3. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
4. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
5. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
6. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal peptides and itch sensation.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2015 Feb; 22(1):29-33. PubMed ID: 25485517
[TBL] [Abstract][Full Text] [Related]
8. NK-1 Antagonists and Itch.
Ständer S; Luger TA
Handb Exp Pharmacol; 2015; 226():237-55. PubMed ID: 25861784
[TBL] [Abstract][Full Text] [Related]
9. Esmolol activates endogenous neurokinin activity inhibiting infarction-induced arrhythmias in rats: novel mechanisms of anti-arrhythmia.
Wang LL; Han Y; Guo Z; Han SQ; Liu T
Regul Pept; 2013 Sep; 186():116-22. PubMed ID: 23994276
[TBL] [Abstract][Full Text] [Related]
10. NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Leonard AV; Thornton E; Vink R
PLoS One; 2014; 9(5):e98364. PubMed ID: 24859234
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.
Vinet-Oliphant H; Alvarez X; Buza E; Borda JT; Mohan M; Aye PP; Tuluc F; Douglas SD; Lackner AA
Am J Pathol; 2010 Sep; 177(3):1286-97. PubMed ID: 20671267
[TBL] [Abstract][Full Text] [Related]
13. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon.
Maggi CA; Patacchini R; Meini S; Quartara L; Sisto A; Potier E; Giuliani S; Giachetti A
Br J Pharmacol; 1994 May; 112(1):150-60. PubMed ID: 7518302
[TBL] [Abstract][Full Text] [Related]
15. Role of substance P in the cardiovascular system.
Mistrova E; Kruzliak P; Chottova Dvorakova M
Neuropeptides; 2016 Aug; 58():41-51. PubMed ID: 26706184
[TBL] [Abstract][Full Text] [Related]
16. IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.
Roh YS; Choi J; Sutaria N; Belzberg M; Kwatra MM; Kwatra SG
Drugs; 2021 Jun; 81(8):895-905. PubMed ID: 33881741
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour.
Trower MK; Fisher A; Upton N; Ratti E
Exp Dermatol; 2014 Nov; 23(11):858-60. PubMed ID: 25078633
[TBL] [Abstract][Full Text] [Related]
18. Acute versus chronic phase mechanisms in a rat model of CRPS.
Wei T; Guo TZ; Li WW; Kingery WS; Clark JD
J Neuroinflammation; 2016 Jan; 13():14. PubMed ID: 26785976
[TBL] [Abstract][Full Text] [Related]
19. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
20. Drugs on the Horizon for Chronic Pruritus.
McEwen MW; Fite EM; Yosipovitch G; Patel T
Dermatol Clin; 2018 Jul; 36(3):335-344. PubMed ID: 29929605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
